Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -74,676 | -57,791 | -31,467 | -15,247 | -139,674 |
| Depreciation Amortization | -8,521 | -5,644 | -3,935 | -2,211 | -7,872 |
| Accounts receivable | -52,482 | -31,590 | -31,696 | -17,139 | -38,829 |
| Accounts payable and accrued liabilities | 14,622 | -1,114 | 6,096 | 80 | 1,057 |
| Other Working Capital | -54,097 | -44,430 | -28,431 | -30,524 | -29,577 |
| Other Operating Activity | 101,977 | 80,470 | 55,859 | 30,925 | 90,696 |
| Operating Cash Flow | $-73,177 | $-60,099 | $-33,574 | $-34,116 | $-124,199 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -322 | -749 | -53 | N/A | -269 |
| Purchase Of Investment | -739,679 | -482,077 | -169,570 | -81,046 | -415,269 |
| Sale Of Investment | 404,851 | 297,568 | 193,568 | 97,225 | 521,079 |
| Investing Cash Flow | $-335,150 | $-185,258 | $23,945 | $16,179 | $105,541 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 567,508 | 561,902 | 555,168 | 9,989 | 17,810 |
| Financing Cash Flow | $567,508 | $561,902 | $555,168 | $9,989 | $17,810 |
| Beginning Cash Position | 149,517 | 149,517 | 149,517 | 149,517 | 150,365 |
| End Cash Position | 308,698 | 466,062 | 695,056 | 141,569 | 149,517 |
| Net Cash Flow | $159,181 | $316,545 | $545,539 | $-7,948 | $-848 |
| Free Cash Flow | |||||
| Operating Cash Flow | -73,177 | -60,099 | -33,574 | -34,116 | -124,199 |
| Capital Expenditure | -322 | -749 | -53 | N/A | -269 |
| Free Cash Flow | -73,499 | -60,848 | -33,627 | -34,116 | -124,468 |